Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtre
1.
Article Dans Anglais | IMSEAR | ID: sea-135045

Résumé

Background: It has been pointed that cueing techniques may have influence upon gait training in Parkinson’s disease (PD). Objective: Study the effects of music cue on treadmill training in PD patients. Subject and methods: A randomized single-blind controlled trial was conducted. Thirty male PD patients, aged 60 to 80 years with Hoehn and Yahr stage 2-3 were allocated into three groups (each 10 patients). Group A: treadmill with music three days and home walking three days/week, Group B: treadmill three days and home walking three days/week, and Group C: home walking six days/week. Each group received four weeks training followed by selfpractice for other four weeks. Gait performances at pre-program, fourth, and eighth week were compared. Results: The results showed that A, B, and C, stride length gained 12%, 5.2%, and 6.7% (p=0.042), walking-speed gained 8.6%, 6.5%, and -2.4%, six-minute walk distance gained 10.2%, 5.4%, and 2.9%, and Timed Up and Go (TUG) gained 14.2%, 12.5%, and 7.6%. Conclusion: Music cue enhanced gait training in mild to moderate PD patients.

2.
Article Dans Anglais | IMSEAR | ID: sea-45421

Résumé

The mainstay of treatment for Parkinson's Disease (PD) remains symptomatic despite the rapid expansion in knowledge of its neurodegenerative process. Therapeutic options, both medical and surgical, have been markedly improved over the past decades, resulting in better motor function, activities of daily living, and quality of life for PD patients. The principle of PD management should be individualized and the selection of treatments should aim to control symptoms as well as to prevent or delay motor complications. In Thailand, various pharmacologic and surgical options are available, including different formulations of levodopa, dopamine agonists, monoamine oxidase B inhibitor, cathechol-O-methyltransferase inhibitor pallidotomy, and lastly deep brain stimulation. The use of dopamine agonists in early PD has a levodopa-sparing effect and reduces the incidence of motor complications. Continuous dopaminergic stimulation (CDS), which mimics physiological activation of dopaminergic receptors, has been proposed as a strategy to prevent motor complications. Based on current evidence, practical guidelines in the medical management of different types of motor complications are outlined in the present article according to what are available in Thailand. Surgical interventions should be reserved for patients with intractable motor complications after careful patient selection.


Sujets)
Antiparkinsoniens/administration et posologie , Stimulation cérébrale profonde , Agonistes de la dopamine/administration et posologie , Dyskinésie due aux médicaments/traitement médicamenteux , Humains , Lévodopa/administration et posologie , Inhibiteurs de la monoamine oxydase/administration et posologie , Maladie de Parkinson/thérapie , Thaïlande
3.
Article Dans Anglais | IMSEAR | ID: sea-40270

Résumé

Deep brain stimulation (DBS) has been shown to be a safe and effective method for the treatment of refractory Parkinson's disease and other movement disorders. Traditionally, frame-based stereotactic have been the standard technique commonly used for DBS surgery. With the development of image-guided neurosurgical systems, frameless stereotactic has been increasingly used for tumor resection or biopsy without the use of stereotactic frame. Frameless stereotactic for functional surgery has been recently developed with the accuracy comparable to frame-based stereotactic surgery. The authors report the surgical technique of frameless functional stereotactic for the treatment of movement disorders.


Sujets)
Stimulation cérébrale profonde/instrumentation , Humains , Troubles de la motricité/chirurgie , Neuronavigation/instrumentation , Neurochirurgie/instrumentation , Maladie de Parkinson/chirurgie
4.
Article Dans Anglais | IMSEAR | ID: sea-45205

Résumé

Dementia represents the most common neurodegenerative disorders affecting approximately 5% of the elderly population over age 65 years. At present, different forms of dementia are distinguished, including Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal dementia, and dementia secondary to diseases, such as AIDS dementia. Unlike AD, these atypical dementias are often associated with neurological symptoms, reflecting the localization of the degenerative process rather than the nature of the underlying histopathology. The present article provides an overview of the clinical evaluation of patients with atypical dementia and reviews distinguishing features of atypical dementias that may be confused with AD. The laboratory and imaging evaluation of various types of dementias are described. Current practice guidelines and practice parameters are reviewed as relevant for primary care practitioner.


Sujets)
Sujet âgé , Sujet âgé de 80 ans ou plus , Maladie d'Alzheimer/diagnostic , Démence vasculaire/diagnostic , Diagnostic différentiel , Humains , Maladie à corps de Lewy/diagnostic , Maladie de Parkinson/complications
5.
Article Dans Anglais | IMSEAR | ID: sea-41752

Résumé

Recognized for over 300 years, Tourette's syndrome was originally ascribed as a rare bizarre psychogenic illness. Because of recent advances in research on Tourette's syndrome, this disorder is not only the rarity once thought, but also a common, biological, genetic disorder with a spectrum of neurobehavioral manifestations that wax and wane during its entire natural course. In addition to standard neuroleptics, much progress in Tourette's syndrome research has widened its pharmacotherapy to include alpha2-adrenergic agonists and atypical neuroleptics as well as behavioral modification, adjustments, and different surgical approaches. Despite a myriad of reports, there are still many unresolved facts, which stimulate research into the underlying mechanisms of this complex neuropsychiatric disorder. We anticipate that continued success of research in this area will lead to molecular insights, identification of vulnerable genes, and eventually novel therapies that can target all aspects of this complex disorder.


Sujets)
Humains , Syndrome de Tourette/diagnostic
6.
Article Dans Anglais | IMSEAR | ID: sea-44092

Résumé

Recognized for over 300 years, Tourette's syndrome was originally ascribed as a rare bizarre psychogenic illness. Because of recent advances in research on Tourette's syndrome, this disorder is not only the rarity once thought, but also a common, biological, genetic disorder with a spectrum of neurobehavioral manifestations that wax and wane during its entire natural course. In addition to standard neuroleptics, much progress in Tourette's syndrome research has widened its pharmacotherapy to include alpha2-adrenergic agonists and atypical neuroleptics as well as behavioral modification, adjustments, and different surgical approaches. Despite a myriad of reports, there are still many unresolved facts, which stimulate research into the underlying mechanisms of this complex neuropsychiatric disorder. We anticipate that continued success of research in this area will lead to molecular insights, identification of vulnerable genes, and eventually novel therapies that can target all aspects of this complex disorder.


Sujets)
Agonistes alpha-adrénergiques/usage thérapeutique , Neuroleptiques/usage thérapeutique , Trouble déficitaire de l'attention avec hyperactivité/diagnostic , Diagnostic différentiel , Humains , Trouble obsessionnel compulsif/diagnostic , Facteurs temps , Syndrome de Tourette/diagnostic
SÉLECTION CITATIONS
Détails de la recherche